Physician profile
Thomas Clements
NPI 1679730295
$6,915.62
in general payments reported to CMS, 2019-2025
24 companies · $218 in 2025
The $218 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,361 · 2020: $2,933 · 2021: $633 · 2022: $896 · 2023: $256 · 2024: $618 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $847 · Travel and Lodging: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $847.37 |
| Travel and Lodging | $244.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,693.20 | 2019-2022 | |
| Dendreon Pharmaceuticals LLC | $1,446.10 | 2019-2020 | |
| Intuitive Surgical, INC. | $850.87 | 2022-2024 | |
| Janssen Biotech, INC. | $799.17 | 2019-2022 | |
| Abbvie INC. | $694.73 | 2019-2025 | Botox |
| Ferring Pharmaceuticals INC. | $205.44 | 2019-2024 | Adstiladrin |
| Bayer Healthcare Pharmaceuticals INC. | $197.71 | 2019-2021 | |
| Boston Scientific Corporation | $181.82 | 2020-2025 | Therasphere Y90 Glass Microspheres 10 Gbq, Embold Fibered |
| Endo Pharmaceuticals INC. | $145.46 | 2019-2020 | |
| Allergan, INC. | $132.88 | 2019-2021 | |
| Urogen Pharma, INC. | $122.12 | 2021-2024 | Jelmyto |
| Teleflex LLC | $78.85 | 2022-2024 | Urolift |
| Pfizer INC. | $62.61 | 2019-2023 | |
| Clinigen, INC. | $53.73 | 2019-2020 | |
| Amgen INC. | $51.57 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $48.69 | 2019-2020 | |
| 180 Medical, INC. | $29.33 | 2019 | |
| Palette Life Sciences, INC. | $25.80 | 2022 | |
| Merck Sharp & Dohme LLC | $25.22 | 2024 | Keytruda |
| Janssen Pharmaceuticals, INC | $17.08 | 2019-2021 | |
| Laborie Medical Technologies Corp. | $16.31 | 2025 | |
| Becton, Dickinson and Company | $12.40 | 2019 | |
| Clovis Oncology, INC. | $12.40 | 2020 | |
| Emd Serono, INC. | $12.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Clements listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.